HTG Molecular to Present Corporate Overview at the Canaccord Genuity 39th Annual Growth Conference

TUCSON, Ariz., July 25, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that John Lubniewski, President and CEO, will present a corporate overview at the Canaccord Genuity 39^th Annual Growth Conference, being held in Boston, Massachusetts on August 7-8, 2019.

About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 535-7742
Email: arr@lifesciadvisors.com

Shaun McMeans
Chief Financial Officer
HTG Molecular Diagnostics
Email: smcmeans@htgmolecular.com